Latest Market Access News

Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.

De.mem Limited reported a 20% increase in revenue to $29.9 million for FY2025, alongside a reduced net loss and its first full-year positive adjusted EBITDA. The company also completed the acquisition of Core Chemicals, expanding its specialty chemicals footprint in the gold mining sector.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Channel Infrastructure reported steady FY25 financials with record throughput and key project progress, while raising dividends and expanding into Australia via a strategic pipeline stake.

PointsBet Holdings Limited reports a 4% revenue increase in H1 FY26 following MIXI’s acquisition of a controlling stake, with contrasting performances in Australia and Canada shaping the group’s outlook.

Australia’s ANSTO has independently confirmed that Lindian Resources’ Kangankunde monazite concentrate is exempt from radioactive transport classification, simplifying export logistics and lowering downstream costs.

EcoGraf Limited has completed a comprehensive update to its Bankable Feasibility Study for the Epanko Graphite Project, confirming robust financials and a production increase to 73,000 tonnes per annum. The study underpins advanced project financing and highlights significant expansion potential amid rising global graphite demand.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Caravel Minerals confirms its Definitive Feasibility Study for the Caravel Copper Project remains on track for mid-2026, while regulatory water investigations push the Final Investment Decision to late 2027. Meanwhile, strategic talks with Adani advance steadily.

Amaero Ltd has announced plans to re-domicile from Australia to the United States, aiming to tap into larger capital markets and position itself for a potential US IPO by late 2026 or early 2027. The move retains its ASX listing while opening doors to broader investor pools and strategic growth opportunities.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

Tivan Limited has submitted a confidential draft Feasibility Study for its Speewah Fluorite Project to key partners, marking a significant step towards project finalisation and potential production.